Open an account

Standard BioTools

LAB · NASDAQ

$0.6373−$0.006 (−0.93%)TodayMarket closed ·
Prev close $0.6433

About LAB

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in Boston, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2011-02-10. The firm develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The firm's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.

Employees
385
Headquarters
Boston, Massachusetts
Listed
Feb 10, 2011
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
standardbio.com

LAB key statistics

Market cap
250.19M
Price-earnings ratio
2.92
Dividend yield
—
Average volume
871.71K
Volume
561.38K
Open price
$0.64
High today
$0.6531
Low today
$0.618
52 Week high
$1.72
52 Week low
$0.62

Standard BioTools (LAB) at a glance

Standard BioTools (LAB) last traded at $0.6373, with a market cap of 250.19M and a price-to-earnings ratio of 2.92.

Today the stock has traded between $0.618 and $0.6531. The current price is 3.1% above the day's low and 2.4% below its high.

Volume so far is 561.38K shares, below the average of 871.71K shares a day.

Over the past year Standard BioTools has ranged from $0.62 to $1.72, and now sits 2% of the way up that range.

Standard BioTools met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.03 per share against an estimate of -$0.0131.

The average analyst price target is $1.38, 116.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 2 analystsAvg $1.38
Low
$1.36
Now
$0.6373
High
$1.42

LAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 250.5% on average.

  1. Q3 FY24: reported -$0.07 per share against an estimate of -$0.0909
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.0707
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.0758
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.0808
  5. Q3 FY25: reported -$0.09 per share against an estimate of -$0.0556
  6. Q4 FY25: reported $0.05 per share against an estimate of -$0.0707
  7. Q1 FY26: reported $0.33 per share against an estimate of -$0.0471
  8. Q2 FY26: reported -$0.03 per share against an estimate of -$0.0131

LAB news

  • Press releasePRNewswire

    Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Proxy and Looming Shareholder Merger Vote --VRME, VAL, LAB and FTHM

  • Press releasePRNewswire

    INVESTOR ALERT: The M&A Class Action Firm Launches Investigation of the Merger--IRDM, VRME, VAL and LAB

  • Press releasePRNewswire

    Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB

  • Press releasePRNewswire

    Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders

  • Avi Kapoor

    Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings

Similar companies

Companies in the same industry as Standard BioTools

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.